Small immunohistochemical studies found PD-L1 expression in up to 70% of ACC samples [38] and 18% of MPPGL samples [37], suggesting that several patients with ACC and some patients with MPPGL may benefit from checkpoint inhibitors, such as avelumab, nivolumab, or pembrolizumab. The gene discussed is CD274; the disease is adrenal cortex carcinoma.